Quanticate Appoints Dr Alison Bond to Lead Pharmacovigilance

24th February 2010

Quanticate, a global biometrics clinical research organisation (CRO), today announced that it has appointed Dr Alison Bond to lead its new pharmacovigilance services team. The appointment further supports Quanticate’s mission in continuing to expand its clinical trial services offerings to support customers around the world.

The new pharmacovigilance service offers clinical trial and post-marketing pharmacovigilance in order to provide comprehensive surveillance throughout the product lifecycle. These services include adverse event case management and reporting, signal detection and evaluation, literature screening and review, and pharmacovigilance document preparation and submission, such as annual safety reports, periodic safety update reports and risk management plans.

“Centralising clinical and safety data with Quanticate creates efficiencies for our customers, hence the addition of pharmacovigilance services. This signals another exciting development for Quanticate and our customers who need to implement rigorous programs that meet regulatory requirements and protect patients,” said Quanticate’s CEO David Underwood. “Alison brings several years of experience and a depth of knowledge in this important area of drug development. Her leadership of our pharmacovigilance services will be of great value to our customers.”

Prior to joining Quanticate, Alison served as an independent pharmacovigilance consultant, leading the set-up of pharmacovigilance systems and completion of pharmacovigilance aspects of an EU marketing authorisation application for a small biopharmaceutical company. Prior to that assignment, she contributed eight years of service to Parexel International, one of the leading global biopharmaceutical service providers, holding senior management positions in medical and pharmacovigilance. In these roles, Alison created and managed global pharmacovigilance systems for a number of pharmaceutical and biotech companies, through all phases of clinical development and post-marketing. Alison also led the UK team of drug safety scientists and helped to develop and improve systems and processes for their global pharmacovigilance services. She gained a PhD in the field of rheumatology and has nine years of pre-clinical research experience.

More About This Company